Top-News

Jazz Pharmaceuticals Aktie News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
170,63 $
+3,72 $
+2,23%
146,57 € 21:09:33 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,36 Mrd. €
Streubesitz
-
KGV
-
neu: Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,29: JZ02F9
Werbung

Jazz Pharmaceuticals News

05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
01.07.25 - PR Newswire
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR ...
10.06.25 - PR Newswire
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-​Line Maintenance Treatment of Extensive-​Stage Small Cell Lung ...
09.06.25 - PR Newswire
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals Presents Late-​Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-​Line Maintenance Therapy for ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-​hrii) in First-​Line HER2-Positive Metastatic ...
29.05.25 - PR Newswire
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in ...
21.05.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences PR Newswire
21.05.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences PR Newswire
06.05.25 - PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
06.05.25 - PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
30.04.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference PR Newswire
30.04.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference PR Newswire
25.04.25 - PR Newswire
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR Newswire
23.04.25 - PR Newswire
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma PR ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »